Every Form 4 that Cormedix (CRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRMD filings page.
CorMedix Inc. (CRMD) reported that Susan Blum, Chief Financial Officer, had 8,424 shares of Common Stock disposed of on 2026-08-29 in a transaction coded "F," described as payment of exercise price or tax liability by delivering or withholding securities. Following this transaction, Blum directly owned 124,315 Common Stock shares.
CorMedix Inc. (CRMD) reported that officer Elizabeth Hurlburt, Chief Operating Officer, had 8,076 shares of common stock disposed of on 2026-08-29 in a transaction coded F, described as a payment of exercise price or tax liability by delivering or withholding securities. Following this withholding transaction, she directly holds 270,463 shares of CorMedix common stock.
CorMedix Inc. (CRMD) reported that Chief Legal Officer Beth Zelnick Kaufman had 8,424 shares of common stock disposed of on 2026-08-29 in a transaction coded "F," representing payment of exercise price or tax liability by delivering or withholding securities. Following this withholding transaction, she directly holds 260,684 shares of CorMedix common stock.
CorMedix Inc. insider filing shows a new equity award to its Chief Legal Officer. Beth Zelnick Kaufman received 36,006 shares of common stock on February 4, 2026 at a price of $0.00, following achievement of performance stock unit (PSU) goals for the first of three performance periods.
The PSUs were originally granted on January 2, 2025 and remain subject to additional time-based vesting conditions before fully vesting. After this award, she beneficially owns 269,108 shares of CorMedix common stock directly.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.
The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.
CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco. On February 4, 2026, he acquired 77,156 shares of common stock at $0.00 per share, following the achievement of performance stock units for the first of three performance periods granted on January 2, 2025.
After this transaction, Todisco beneficially owned 774,749 shares of CorMedix common stock, held directly. The performance stock units remain subject to time-based vesting conditions that must be satisfied by the reporting person before full vesting.
CorMedix Inc. Chief Financial Officer Susan Blum reported equity compensation and related share withholding transactions. On 01/23/2026, she was granted 72,820 restricted stock units, each representing one share of CorMedix common stock at a stated price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, 9,767 shares of common stock were disposed of at $7.27 per share in a transaction coded "F," typically indicating shares withheld to cover taxes. After these transactions, Blum directly owned 132,739 shares of CorMedix common stock.
CorMedix Inc.'s Chief Legal Officer Beth Zelnick Kaufman reported equity compensation activity in the company’s common stock. On 01/23/2026 she received an award of 72,820 restricted stock units at a price of $0.00 per unit, each representing one share of common stock.
The restricted stock units vest 25% on the grant date and, subject to continued employment, 25% on each of the first, second, and third anniversaries of the grant date. On the same day, 8,803 shares were withheld at $7.27 per share, typically for tax obligations, leaving her with 233,102 directly owned shares after the reported transactions.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported equity compensation and a related share sale. On 01/23/2026 she received 93,010 shares of common stock for $0.00 per share as a grant of restricted stock units that convert into common stock.
The restricted stock units vest 1/4 at grant and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant date. On the same day, 10,778 shares of common stock were disposed of at $7.27 per share, typically reflecting shares withheld or sold to cover taxes, leaving her with 242,533 directly owned shares.
CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction. On 01/23/2026, he received 225,900 restricted stock units, each representing one share of common stock, at a price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, a second transaction labeled code F covered 27,306 shares at $7.27 per share, leaving Todisco with 697,593 common shares held directly.
CorMedix Inc. director Myron Kaplan received an equity grant of 30,453 restricted stock units on January 26, 2026. The Form 4 shows these RSUs were awarded at a price of $0.00 per unit and will vest in full on January 26, 2027, subject to his continued service through that date.
Following this grant, Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. The filing also notes additional indirect holdings of 20,000 shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he expressly disclaims beneficial ownership.
CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units. The units were issued on January 26, 2026 at a stated price of $0.00 per share and represent a right to receive an equal number of common shares.
The restricted stock units will vest in full on January 26, 2027, conditioned on continued service through that date. Following this grant, Dillione beneficially owns 68,926 shares of CorMedix common stock in direct ownership.
CorMedix Inc. director Steven W. Lefkowitz reported receiving 30,453 shares of common stock on January 26, 2026 as restricted stock units granted at $0.00 per share. These units each represent one share of common stock and will vest in full on January 26, 2027, subject to his continued service.
After this grant, he beneficially owns 125,951 shares directly. He also has indirect beneficial ownership of 30,152 shares through the Wade Capital Corporation Money Purchase Plan, where he has voting and investment control, and 2,000 shares held by his spouse.
CorMedix Inc. director Alan W. Dunton received an equity award in the form of restricted stock units. On January 26, 2026, he was granted 30,453 restricted stock units of CorMedix common stock at a grant price of $0.00 per unit, increasing his beneficial ownership to 70,703 shares.
Each restricted stock unit represents the right to receive one share of common stock. The units will vest in full on January 26, 2027, provided he continues serving the company through the vesting date.
CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting an equity compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of CorMedix common stock. The RSUs will vest in full on January 26, 2027, provided Scott continues his service through the vesting date. After this grant, he beneficially owns 68,786 shares of CorMedix common stock in direct ownership form.
CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share. Following this grant, he beneficially owns 66,453 CorMedix shares directly.
The award consists of restricted stock units issued on January 26, 2026. Each unit converts into one share of common stock and will vest in full on January 26, 2027, provided he continues to serve through the vesting date.
CorMedix Inc. director Janet Dillione reported a sale of company stock. On January 21, 2026, she sold 10,000 shares of CorMedix common stock at a weighted average price of $6.88 per share, in multiple trades executed between $6.85 and $6.90 per share. After this transaction, she beneficially owned 38,473 shares of CorMedix common stock directly.
The filing notes that the reported price is an average across several individual trades, and the director has agreed to provide detailed trade and pricing information to regulators, the company, or any security holder who requests it.
CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported a Form 4 insider transaction involving company common stock. On 01/12/2026, a transaction coded "F" was reported for 5,794 shares of common stock at a price of $7.15 per share. Following this transaction, she directly beneficially owned 160,301 shares of CorMedix common stock. The filing notes that the transaction is being reported late due to an inadvertent administrative error.
CorMedix Inc. Chief Executive Officer Joseph Todisco, who also serves as a director, reported equity award-related transactions in the company’s common stock. On 01/16/2026, he exercised a stock option for 29,585 shares of common stock at an exercise price of $3.38 per share from an option originally granted on 5/10/2022, increasing his directly held common stock to 521,664 shares and leaving 411,245 options outstanding. The filing also reports transactions coded “F” on 01/12/2026 for 17,417 shares at $7.15 and on 01/17/2026 for 22,665 shares at $6.78, after which he directly held 492,079 and then 498,999 common shares. A footnote explains that the option exercise price was paid in cash and that no sales of stock were made. Another footnote states the Form 4 is being reported late due to an inadvertent administrative error.
CorMedix Inc.’s Chief Commercial Officer, Michael David Seckler, reported an equity compensation grant of 133,156 shares of common stock on 01/08/2026. The filing shows these as restricted stock units, each representing the right to receive one share of CorMedix common stock at a stated price of $0 per unit.
The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, and vesting requires Mr. Seckler to remain employed through each applicable vesting date. After this grant, he beneficially owns 133,156 shares directly.
CorMedix Inc. director Steven W. Lefkowitz reported exercising stock options for 15,000 shares of common stock on January 12, 2026. The options had an exercise price of $5.63 per share, and he paid the exercise price in cash. The filing states that no sales of stock were made in connection with this transaction.
After the option exercise, Lefkowitz directly beneficially owns 95,498 shares of CorMedix common stock. He also indirectly beneficially owns 30,152 shares through the Wade Capital Corporation Money Purchase Plan, an entity for which he has voting and investment control, and an additional 2,000 shares are held indirectly through his wife. The exercised option covering 15,000 shares was fully vested and now shows a remaining balance of zero.
CorMedix Inc.'s Chief Legal Officer reported an insider share transaction. A Form 4 filing shows a transaction in CorMedix Inc. common stock on January 2, 2026, coded "F". The transaction involved 11,333 shares at a price of $12.16 per share. Following this activity, the reporting person directly beneficially owns 169,085 shares of CorMedix common stock.
CorMedix Inc. director Janet Dillione reported exercising stock options and selling shares of the company’s common stock on 12/09/2025. She exercised options to buy 19,000 shares at $9.55 per share and another 15,000 shares at $5.63 per share, receiving a total of 34,000 shares.
On the same day, she sold 34,000 shares of CorMedix common stock at a weighted average price of $12.00 per share, with individual trades ranging from $12.00 to $12.02. After these transactions, she directly owned 48,473 shares of CorMedix common stock. The exercised options, originally granted in 2016 and 2020 and now fully vested, were reduced to zero following the transactions.
CorMedix Inc. director Steven Lefkowitz reported an open-market sale of common stock. On 12/09/2025, he sold 40,000 shares of CorMedix common stock at a weighted average price of $11.88 per share, with individual trades executed between $11.87 and $11.92. After this transaction, he directly owned 80,498 shares of CorMedix common stock.
In addition to his direct holdings, Lefkowitz is reported to beneficially own 30,152 shares through the Wade Capital Corporation Money Purchase Plan, for which he has voting and investment control, and 2,000 shares held by his wife. The filing reflects a routine insider ownership update rather than a company-level financing or operational event.
CorMedix Inc. (CRMD) director reports stock sale. A company director filed a Form 4 disclosing the sale of 30,000 shares of CorMedix common stock on 11/14/2025 at a weighted average price of $11.42 per share. The trades were executed in multiple transactions at prices ranging from $11.41 to $11.44. After this sale, the director beneficially owns 48,473 shares of CorMedix common stock in direct ownership.
CorMedix Inc. (CRMD) director reported an open‑market purchase of 25,000 shares of common stock on 10/23/2025 at a weighted average price of $11.02 (transactions ranged from $11.01 to $11.03), coded “P” for purchase.
Following the transaction, the reporting person beneficially owns 201,034 shares directly. The filing also lists 20,000 shares held indirectly by a spouse and 10,000 shares held indirectly as spouse acting as guardian for grandchildren; beneficial ownership of these indirect holdings is disclaimed.
CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.
Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.
CorMedix Inc. insider Beth Zelnick Kaufman reported multiple transactions on 09/09/2025. She acquired 50,000 shares by exercising options at an exercise price of $3.30 (options originally granted 12/12/2023, vesting over four years). On the same date she disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82. Following these trades her beneficial ownership is reported as 180,418 shares.
Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), reported option exercises and subsequent open-market sales in September 2025. On 09/09/2025 she exercised 12,876 stock options at an exercise price of $1.45 and sold 12,876 shares at a weighted average price of $13.51. On 09/11/2025 she exercised 41,121 options at $1.45 and sold 41,121 shares at a weighted average price of $13.08. Following these transactions her beneficial ownership is reported as 176,990 shares. The exercised options were originally granted 03/19/2018 with scheduled vesting and milestone-based vesting for remaining amounts.